HK52196A - Use of omeprazole as an antimicrobial agent - Google Patents

Use of omeprazole as an antimicrobial agent Download PDF

Info

Publication number
HK52196A
HK52196A HK52196A HK52196A HK52196A HK 52196 A HK52196 A HK 52196A HK 52196 A HK52196 A HK 52196A HK 52196 A HK52196 A HK 52196A HK 52196 A HK52196 A HK 52196A
Authority
HK
Hong Kong
Prior art keywords
omeprazole
salt
pct
antimicrobial agent
methoxy
Prior art date
Application number
HK52196A
Other languages
English (en)
French (fr)
Inventor
Tomoi Masaaki
Ikeda Yoshifumi
Yokota Yoshiko
Original Assignee
Aktiebolaget Hassle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12300238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK52196(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aktiebolaget Hassle filed Critical Aktiebolaget Hassle
Publication of HK52196A publication Critical patent/HK52196A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (1)

  1. Verwendung von 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]-sulfinyl]-1H-benzimidazol oder eines pharmazeutisch akzeptablen Salzes davon zur Herstellung eines Medikaments zur Behandlung von Campylobacter-Infektionen.
HK52196A 1989-02-09 1996-03-21 Use of omeprazole as an antimicrobial agent HK52196A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1030311A JP2694361B2 (ja) 1989-02-09 1989-02-09 抗菌剤
PCT/SE1990/000070 WO1990009175A1 (en) 1989-02-09 1990-02-02 Use of omeprazole as an antimicrobial agent

Publications (1)

Publication Number Publication Date
HK52196A true HK52196A (en) 1996-03-29

Family

ID=12300238

Family Applications (1)

Application Number Title Priority Date Filing Date
HK52196A HK52196A (en) 1989-02-09 1996-03-21 Use of omeprazole as an antimicrobial agent

Country Status (19)

Country Link
US (1) US5093342A (de)
EP (1) EP0414847B1 (de)
JP (1) JP2694361B2 (de)
KR (1) KR0140236B1 (de)
AT (1) ATE94063T1 (de)
AU (1) AU626641B2 (de)
CA (1) CA2025668C (de)
CY (1) CY1909A (de)
DE (1) DE69003207T2 (de)
DK (1) DK0414847T3 (de)
ES (1) ES2058892T3 (de)
HK (1) HK52196A (de)
HU (1) HU205253B (de)
IE (1) IE65814B1 (de)
IL (1) IL93263A0 (de)
LV (1) LV10577B (de)
MY (1) MY111737A (de)
PH (1) PH26787A (de)
WO (1) WO1990009175A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69014141T2 (de) * 1989-02-10 1995-05-24 Takeda Chemical Industries Ltd Verwendung von Benzimidazol-Derivaten als antibakterielle Mittel.
GB9018603D0 (en) * 1990-08-24 1990-10-10 Smith Kline French Lab Compositions
WO1992004898A1 (de) * 1990-09-14 1992-04-02 Byk Gulden Lomberg Chemische Fabrik Gmbh Verwendung von pyridylmethylsulfinyl-1h-benzimidazol derivaten zur behandlung durch helicobacter verursachten erkrankungen
IL105155A (en) * 1992-04-24 1999-05-09 Astra Ab Combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic
US5504082A (en) * 1992-06-01 1996-04-02 Yoshitomi Pharmaceutical Industries, Ltd. Pyridine compound and pharmaceutical compostions
EP0673246A1 (de) * 1992-12-10 1995-09-27 Byk Gulden Lomberg Chemische Fabrik GmbH Verwendung von alkylthiopyridinen zur bekämpfung von heliobacter-bakterien
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US5834002A (en) 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
US6902738B2 (en) * 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
AU4596796A (en) * 1995-02-07 1996-08-27 Narayan Krishnarao Athanikar Concomitant treatment with bismuth and antibacterials
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
ATE500815T1 (de) * 1997-12-08 2011-03-15 Dietrich Rango Neue suppositoriumsform mit säureempfindlichem wirkstoff
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
IL137229A0 (en) 1998-01-14 2001-07-24 Uab Research Foundation Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6787342B2 (en) 2000-02-16 2004-09-07 Merial Limited Paste formulations
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
CA2450073C (en) 2001-07-25 2017-08-29 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
WO2003063840A2 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
TWI367759B (en) * 2003-02-20 2012-07-11 Santarus Inc A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2004257864A1 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
CA2531564C (en) * 2003-07-18 2016-01-19 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP2671508B1 (de) 2005-04-28 2020-09-16 Proteus Digital Health, Inc. Pharma-Informatiksystem
DK2003130T3 (da) 2006-03-10 2011-12-12 Arigen Pharmaceuticals Inc Nyt pyridinderivat med anti-helicobacter pylori-aktivitet
JP2010503710A (ja) 2006-09-18 2010-02-04 ラプトール ファーマシューティカル インコーポレイテッド 受容体関連タンパク質（ｒａｐ）結合体の投与による肝障害の処置
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
ES2390611T3 (es) 2006-12-18 2012-11-14 Arigen Pharmaceuticals, Inc. Agente de erradicación de Helicobacter pylori que tiene actividad inhibidora sobre la secreción de ácido gástrico
ES2919563T3 (es) 2009-02-20 2022-07-27 Enhanx Biopharm Inc Sistema de administración de medicamentos a base de glutatión
EP2420500A4 (de) 2009-04-09 2012-09-05 Arigen Pharmaceuticals Inc Pyridinthioderivat sowie pharmazeutische zusammensetzung damit und mit anti-helidobacter-pylori-wirkung
KR20180114970A (ko) 2009-05-06 2018-10-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US8992897B2 (en) 2010-01-06 2015-03-31 Elc Management Llc Skin lightening compositions
US8722026B2 (en) * 2010-01-06 2014-05-13 Elc Management, Llc Skin lightening compositions
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
KR101628474B1 (ko) * 2014-08-27 2016-06-08 경북대학교 산학협력단 오메프라졸을 유효성분으로 포함하는 피부 미백용 화장료 조성물
JP2025532389A (ja) 2022-10-04 2025-09-29 ザビリュク，アルセニー 大動脈弁の石灰化の抑制

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
KR890701580A (ko) * 1987-10-30 1989-12-21 앤더스 베딘 골(骨)손실에 관련된 질병 치료용 2-피리디닐메틸(술피닐 또는 티오) 벤즈이미다졸

Also Published As

Publication number Publication date
DE69003207D1 (de) 1993-10-14
HUT54890A (en) 1991-04-29
DE69003207T2 (de) 1994-02-03
CY1909A (en) 1990-02-02
LV10577B (en) 1995-10-20
PH26787A (en) 1992-10-13
AU5038190A (en) 1990-09-05
KR910700048A (ko) 1991-03-13
ATE94063T1 (de) 1993-09-15
HU205253B (en) 1992-04-28
JP2694361B2 (ja) 1997-12-24
ES2058892T3 (es) 1994-11-01
JPH02209809A (ja) 1990-08-21
KR0140236B1 (ko) 1998-06-01
EP0414847B1 (de) 1993-09-08
EP0414847A1 (de) 1991-03-06
US5093342A (en) 1992-03-03
IE900418L (en) 1990-08-09
WO1990009175A1 (en) 1990-08-23
HU901539D0 (en) 1991-02-28
IE65814B1 (en) 1995-11-15
MY111737A (en) 2000-12-30
CA2025668C (en) 1998-09-15
CA2025668A1 (en) 1990-08-10
LV10577A (lv) 1995-04-20
AU626641B2 (en) 1992-08-06
IL93263A0 (en) 1990-11-29
DK0414847T3 (da) 1993-12-13

Similar Documents

Publication Publication Date Title
EP0414847B1 (de) Verwendung von omeprazol als antimikrobielles mittel
EP0382489B1 (de) Verwendung von Benzimidazol-Derivaten als antibakterielle Mittel
AU2003210400B2 (en) Form of presentation for 3-[(2-{[4-hexyloxycarbonylamino-imino -methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester to be administered orally
EP0565210B1 (de) Vehikel für die orale Verarbreichung säurelabiler Pharmaka
HRP20020182A2 (en) Benzamide formulation with histone deacetylase inhibitor activity
IE58278B1 (en) Long-acting formulation of cefaclor
SI8710681A8 (en) Process for obtaining new pharmaceutic substance for oral use
HRP930755A2 (en) Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic
JPH0367045B2 (de)
IE57967B1 (en) An antibiotic compound,a method for its preparation and compositions containing it
JP3593357B2 (ja) 抗菌剤
AU665043B2 (en) Substituted benzimidazoles, process for their preparation as well as their use
JPH06500547A (ja) ピリジルメチルスルフィニル―１ｈ―ベンゾイミダゾール誘導体のヘリコバクターにより起こされる病気の治療のための使用
US4233314A (en) Analgesic potentiation
US6426369B1 (en) Oxethazaine as antimicrobial agent
US6017950A (en) Methods for controlling gram negative bacteria in mammals
US4312879A (en) Clonidine and lofexidine as antidiarrheal agents
JPH0769888A (ja) 抗菌剤
SK19192000A3 (sk) Použitie paroxetínu alebo jeho farmaceuticky prijateľnej soli alebo solvátu na podporu odvykania od fajčenia alebo na zníženie alebo prevenciu relapsu fajčenia
AU592097B2 (en) Method for the treatment and/or prophylaxis of hyperglycaemia
JPH09221422A (ja) シクロオキシゲナーゼ−２の作用増強剤
JPH03161440A (ja) 抗菌剤
JPH0977766A (ja) ４−アミノ−５−ピリミジンカルボン酸誘導体を有効 成分とする抗菌剤
EP0369503A1 (de) Methode zur Kontrolle von Pneumocystis carinii
EP1057487A1 (de) Antimicrobielle zusammenstellungen mit synergistischem effekt, diese enthaltende arzneimittel und heilverfahren für verdauungskrankheiten, deren herstellungsverfahren und damit verbundene zusammenstellungen

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090202